SelectQuote Q4 FY2026: Cash Flow Improved, but Medicare Growth Is Moving the Other Way

Farzin Espahani

Strategic Advisor, Insurance Growth, Medicare Distribution, and Compliance · LinkedIn

SelectQuote reported fiscal fourth-quarter and full-year 2026 results on August 25, 2026. The market reaction was severe.

The company missed Wall Street expectations for both quarterly revenue and earnings, guided to a sizable revenue decline in fiscal 2027, and expects Medicare Advantage approved policies to fall another 10% to 15% next year.

SelectQuote shares closed August 25 at approximately $0.55, down 29.3% for the day.

There is, however, one part of the report that deserves more attention: SelectQuote is converting more of its business into cash.

That matters because the Medicare distribution market is becoming less forgiving of growth that requires substantial upfront acquisition spending while cash arrives over several years.

Q4 2026 at a glance

SelectQuote's quarterly revenue fell and Medicare Advantage policy production contracted substantially. At the same time, adjusted EBITDA increased and quarterly operating cash burn fell from $37.5 million to $3.3 million.

That combination explains much of the tension in the report.

The strongest number was operating cash flow

For the full fiscal year, SelectQuote generated $31.9 million of operating cash flow compared with an $11.7 million cash outflow in fiscal 2025.

That is an approximately $44 million year-over-year improvement.

Revenue grew about 6% for the year to $1.62 billion, while adjusted EBITDA declined from $126.3 million to $109.1 million. The improvement in cash flow therefore cannot simply be attributed to rapidly expanding earnings.

The business is becoming better at converting its existing economics into cash.

That is particularly relevant for an insurance distributor. Medicare distribution businesses frequently incur customer-acquisition expenses before collecting all of the commissions associated with a policy. SelectQuote ended fiscal 2026 with a large commissions-receivable asset built from policies written in prior periods.

Management is now emphasizing harvesting more cash from that installed base while being more selective about how aggressively it funds new Medicare Advantage growth.

For fiscal 2027, SelectQuote expects operating cash flow to exceed $60 million and free cash flow to reach roughly $50 million.

That forecast is one of the most consequential numbers in the report. It also remains a forecast. Investors will need to see the cash appear on the cash-flow statement over the next several quarters.

Medicare Advantage volume remains under pressure

SelectQuote's Senior segment shows what is happening across parts of Medicare Advantage distribution.

Fourth-quarter Medicare Advantage approved policies fell 15% year over year, from 85,344 to 72,180. Submitted policies were down 19%. For the full fiscal year, approved Medicare Advantage policies declined 4%.

Management expects another 10% to 15% decline in approved Medicare Advantage policies during fiscal 2027.

This reflects conditions extending beyond SelectQuote. Medicare Advantage carriers have been adjusting benefits, pricing, geographic footprints and distribution volumes as they work to restore plan-level margins. That changes the economics for distributors because carrier appetite increasingly determines where acquisition spending can be deployed profitably.

SelectQuote appears willing to accept lower volume rather than acquire business under economics it considers unattractive.

The Senior business remained profitable despite the contraction. Full-year Senior adjusted EBITDA margin was 26%, compared with 27% a year earlier and above management's stated long-term target of more than 20%.

That margin durability is meaningful. The question is how long SelectQuote can maintain those economics if Medicare Advantage production continues declining.

The increase in lifetime value deserves some context

Fourth-quarter Medicare Advantage lifetime value (LTV) per approved policy increased 5%, from $837 to $883. That indicates better expected economics on policies written during the quarter.

I would be careful about treating the quarterly improvement as a new trend. For the full year, Medicare Advantage LTV was $873 compared with $884 in fiscal 2025, a 1% decline. The quarter improved. The full-year trend did not.

For distributors, this distinction matters because lifetime value depends on commission rates, carrier mix, policy persistence and assumptions about future renewals. Higher LTV becomes economically valuable when the underlying members persist and the expected commissions are actually collected.

SelectRx is changing the economics of the company

SelectQuote is increasingly becoming more than a Medicare insurance distributor.

Healthcare Services generated approximately $845 million of fiscal 2026 revenue, up 14% year over year, making it SelectQuote's largest revenue segment. SelectRx membership increased only 1%, from 108,018 to 109,039.

The more interesting operating metric was prescription activity. Average prescriptions shipped per business day increased from 27,867 in fiscal 2025 to 32,215 in fiscal 2026, roughly a 16% increase. This suggests SelectQuote is generating more activity from its existing pharmacy population rather than relying entirely on member growth.

Management also said Healthcare Services exited fiscal 2026 at nearly a $50 million annualized adjusted EBITDA run rate and expects the segment's margin to approximately double in fiscal 2027.

The strategic logic is straightforward. Acquiring a Medicare consumer is expensive. If SelectQuote can responsibly serve some of those consumers through additional healthcare services after the insurance transaction, the economic value of the relationship can extend beyond the original commission. That can improve the return on customer acquisition without requiring equivalent growth in new insurance policies.

The unit economics improved

Another useful measure appears in SelectQuote's combined Senior and Healthcare Services economics over the trailing twelve months:

These figures combine insurance distribution and healthcare-services economics, so they should not be interpreted as standalone Medicare brokerage profitability. They do show why SelectQuote is emphasizing the broader consumer relationship. The company is trying to earn more from each acquired customer while controlling what it spends to acquire the next one.

For healthcare distribution businesses facing tighter carrier budgets, that operating discipline is becoming increasingly important.

Debt keeps cash flow at the center of the discussion

SelectQuote still has substantial leverage. The company reported approximately $370.2 million of total debt obligations as of June 30, 2026, compared with $385.1 million a year earlier. Cash, cash equivalents and restricted cash totaled approximately $21.7 million.

Fiscal 2026 net interest expense was approximately $44.5 million. SelectQuote refinanced its credit structure earlier this year, extending its term-loan maturity to 2031. That gave the company additional time and liquidity, but the debt still carries a meaningful cost.

This is why the operating-cash-flow improvement carries more weight than another percentage point of revenue growth. If SelectQuote can generate more than $60 million of operating cash flow and roughly $50 million of free cash flow in fiscal 2027, management gains more room to reduce debt, lower financing costs and improve financial flexibility. If cash generation misses expectations, leverage becomes much harder for investors to ignore.

Why investors still punished the stock

There was plenty in the report for the market to dislike. Quarterly revenue of $321.7 million missed the roughly $345 million consensus estimate. Adjusted earnings per share also missed expectations.

The larger issue was fiscal 2027 guidance. SelectQuote expects revenue of $1.35 billion to $1.45 billion. The midpoint is approximately 14% below fiscal 2026 revenue and roughly $200 million below the analyst consensus reported before the earnings call.

Management expects Medicare Advantage approved policies to decline 10% to 15%. Healthcare Services revenue is also expected to decline 10% to 15%, partly because of changes associated with the Inflation Reduction Act.

Investors therefore received a company forecasting less revenue and less Medicare production while asking the market to focus on future cash generation. That requires execution.

There is a broader lesson for Medicare distribution

For years, much of Medicare distribution economics was discussed through enrollment growth, policy volume, lead volume and carrier demand. The environment is forcing a broader measurement system.

Operators increasingly need to understand:

• Acquisition cost by carrier and member cohort
• Policy persistence and realized lifetime value
• Revenue collected versus revenue booked
• Downstream service utilization
• Contribution margin by member relationship
• Operating cash conversion
• Carrier profitability and changing distribution appetite

A distributor can write fewer policies and still improve its economic position if it acquires the right policies, retains them longer, controls acquisition costs and creates additional legitimate value from the customer relationship. The opposite is also possible. High enrollment growth can destroy value when acquisition costs, persistency or carrier economics are weak.

That is why visibility across the entire member lifecycle matters.

What I would watch next

SelectQuote gave investors several measurable commitments for fiscal 2027.

• Operating cash flow above $60 million
• Approximately $50 million of free cash flow
• Meaningful Healthcare Services margin expansion despite lower expected revenue

I would also watch whether debt begins declining faster and whether Medicare Advantage lifetime value remains strong as policy production falls. Those numbers will tell us whether SelectQuote is successfully moving from a volume-dependent Medicare distribution model toward a business that can generate durable cash from the customers and infrastructure it has already built.

The fiscal 2026 results provide evidence that the cash-flow transition has started. Fiscal 2027 will show whether it is repeatable.